CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Asensus Surgical, Inc. - ASXC CFD

0.2460
1.32%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0097
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Asensus Surgical Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.2493
Open* 0.2485
1-Year Change* -63.31%
Day's Range* 0.246 - 0.2492
52 wk Range 0.20-1.18
Average Volume (10 days) 1.53M
Average Volume (3 months) 29.33M
Market Cap 77.31M
P/E Ratio -100.00K
Shares Outstanding 264.32M
Revenue 5.61M
EPS -0.33
Dividend (Yield %) N/A
Beta 1.45
Next Earnings Date Feb 29, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 22, 2024 0.2460 -0.0025 -1.01% 0.2485 0.2495 0.2460
Apr 19, 2024 0.2493 0.0001 0.04% 0.2492 0.2540 0.2491
Apr 18, 2024 0.2519 0.0007 0.28% 0.2512 0.2535 0.2471
Apr 17, 2024 0.2504 -0.0129 -4.90% 0.2633 0.2633 0.2492
Apr 16, 2024 0.2666 -0.0006 -0.22% 0.2672 0.2692 0.2462
Apr 15, 2024 0.2693 0.0009 0.34% 0.2684 0.2717 0.2572
Apr 12, 2024 0.2692 -0.0049 -1.79% 0.2741 0.2762 0.2651
Apr 11, 2024 0.2713 0.0020 0.74% 0.2693 0.2757 0.2633
Apr 10, 2024 0.2663 -0.0004 -0.15% 0.2667 0.2732 0.2563
Apr 9, 2024 0.2686 0.0024 0.90% 0.2662 0.2732 0.2609
Apr 8, 2024 0.2633 -0.0003 -0.11% 0.2636 0.2642 0.2592
Apr 5, 2024 0.2643 -0.0051 -1.89% 0.2694 0.2694 0.2525
Apr 4, 2024 0.2642 -0.0200 -7.04% 0.2842 0.2892 0.2592
Apr 3, 2024 0.2781 -0.0011 -0.39% 0.2792 0.2881 0.2597
Apr 2, 2024 0.2074 -0.0112 -5.12% 0.2186 0.2214 0.2016
Apr 1, 2024 0.2129 -0.0163 -7.11% 0.2292 0.2292 0.2129
Mar 28, 2024 0.2253 -0.0079 -3.39% 0.2332 0.2353 0.2219
Mar 27, 2024 0.2263 0.0000 0.00% 0.2263 0.2336 0.2190
Mar 26, 2024 0.2249 -0.0163 -6.76% 0.2412 0.2431 0.2249
Mar 25, 2024 0.2392 0.0049 2.09% 0.2343 0.2440 0.2092

Asensus Surgical, Inc. Events

Time (UTC) Country Event
Thursday, May 9, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Asensus Surgical Inc Earnings Release
Q1 2024 Asensus Surgical Inc Earnings Release

Forecast

-

Previous

-
Wednesday, June 5, 2024

Time (UTC)

15:00

Country

US

Event

Asensus Surgical Inc Annual Shareholders Meeting
Asensus Surgical Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 8, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Asensus Surgical Inc Earnings Release
Q2 2024 Asensus Surgical Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 7.087 8.232 3.175 8.531 24.102
Revenue 7.087 8.232 3.175 8.531 24.102
Cost of Revenue, Total 10.872 11.096 5.166 20.731 16.171
Gross Profit -3.785 -2.864 -1.991 -12.2 7.931
Total Operating Expense 82.766 70.004 63.564 163.106 73.254
Selling/General/Admin. Expenses, Total 34.928 32.718 27.201 46.772 39.59
Research & Development 28.942 19.348 16.621 22.468 21.823
Depreciation / Amortization 7.708 11.254 10.801 10.301 10.868
Unusual Expense (Income) 1.431 -2.847 0.851 72.387 -14.187
Other Operating Expenses, Total -1.115 -1.565 2.924 -9.553 -1.011
Operating Income -75.679 -61.772 -60.389 -154.575 -49.152
Interest Income (Expense), Net Non-Operating 0.731 -1.761 -0.32 -1.783 -17.128
Other, Net -0.295 1.296 -0.119 -0.967 1.126
Net Income Before Taxes -75.243 -62.237 -60.828 -157.325 -65.154
Net Income After Taxes -75.561 -62.462 -59.312 -154.201 -61.777
Net Income Before Extra. Items -75.561 -62.462 -59.312 -154.201 -61.777
Net Income -75.561 -62.462 -59.312 -154.201 -61.777
Income Available to Common Excl. Extra. Items -75.561 -62.462 -60.023 -154.201 -61.777
Income Available to Common Incl. Extra. Items -75.561 -62.462 -60.023 -154.201 -61.777
Diluted Net Income -75.561 -62.462 -60.023 -154.201 -61.777
Diluted Weighted Average Shares 236.492 226.96 70.809 17.737 15.9384
Diluted EPS Excluding Extraordinary Items -0.31951 -0.27521 -0.84767 -8.69375 -3.87599
Diluted Normalized EPS -0.31557 -0.28337 -0.83986 -5.88489 -4.45456
Total Extraordinary Items
Total Adjustments to Net Income 0 -0.711
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1.081 0.976 2.464 2.563 0.994
Revenue 1.081 0.976 2.464 2.563 0.994
Cost of Revenue, Total 3.074 2.947 2.298 4.404 2.347
Gross Profit -1.993 -1.971 0.166 -1.841 -1.353
Total Operating Expense 21.944 23.324 20.591 21.595 20.561
Selling/General/Admin. Expenses, Total 9.573 10.021 8.614 8.468 8.594
Research & Development 8.98 10.139 8.52 6.741 7.253
Depreciation / Amortization 0.114 0.112 0.107 2.398 2.533
Unusual Expense (Income) 0 0.999 0 0.432
Other Operating Expenses, Total 0.203 0.105 0.053 -0.416 -0.598
Operating Income -20.863 -22.348 -18.127 -19.032 -19.567
Interest Income (Expense), Net Non-Operating 0.431 0.439 0.365 0.192 0.119
Other, Net -0.242 -0.218 -0.034 -0.029 -0.086
Net Income Before Taxes -20.674 -22.127 -17.796 -18.869 -19.534
Net Income After Taxes -20.662 -22.218 -17.89 -18.924 -19.619
Net Income Before Extra. Items -20.662 -22.218 -17.89 -18.924 -19.619
Net Income -20.662 -22.218 -17.89 -18.924 -19.619
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -20.662 -22.218 -17.89 -18.924 -19.619
Income Available to Common Incl. Extra. Items -20.662 -22.218 -17.89 -18.924 -19.619
Diluted Net Income -20.662 -22.218 -17.89 -18.924 -19.619
Diluted Weighted Average Shares 239.57 238.28 236.849 236.713 236.505
Diluted EPS Excluding Extraordinary Items -0.08625 -0.09324 -0.07553 -0.07994 -0.08295
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.08625 -0.09324 -0.07279 -0.07994 -0.08177
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 86.873 113.297 34.013 27.955 101.583
Cash and Short Term Investments 70.524 98.391 16.363 9.598 72.851
Cash & Equivalents 6.329 18.129 16.363 9.598 21.061
Total Receivables, Net 2.81 2.06 3.985 3.336 8.595
Accounts Receivable - Trade, Net 2.256 0.749 1.115 0.62 8.56
Total Inventory 8.284 8.634 10.034 10.653 10.941
Prepaid Expenses 3.584 3.255 3.631 4.368 9.196
Total Assets 116.053 186.473 78.258 74.779 239.307
Property/Plant/Equipment, Total - Net 14.492 16.319 11.542 7.006 6.337
Property/Plant/Equipment, Total - Gross 27.172 26.008 25.802 17.974 17.499
Accumulated Depreciation, Total -12.68 -9.689 -14.26 -10.968 -11.162
Goodwill, Net 0 80.131
Intangibles, Net 1.576 9.892 22.267 31.066 50.463
Note Receivable - Long Term
Other Long Term Assets, Total 9.247 9.53 10.436 8.752 0.793
Total Current Liabilities 10.414 9.85 10.283 13.023 21.819
Accounts Payable 3.348 3.448 1.965 3.579 4.433
Accrued Expenses 6.601 5.859 6.301 8.553 9.228
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 1.228 0
Other Current Liabilities, Total 0.465 0.543 0.789 0.891 8.158
Total Liabilities 16.408 17.227 16.689 19.244 70.786
Total Long Term Debt 0 0 1.587 0 28.937
Long Term Debt 0 1.587 0 28.937
Deferred Income Tax 0 1.392 4.72
Other Liabilities, Total 5.994 7.377 4.819 4.829 15.31
Total Equity 99.645 169.246 61.569 55.535 168.521
Common Stock 0.237 0.235 0.116 0.021 0.216
Additional Paid-In Capital 962.731 954.649 781.397 720.484 676.373
Retained Earnings (Accumulated Deficit) -860.935 -785.374 -722.912 -663.6 -509.406
Treasury Stock - Common
Other Equity, Total -2.388 -0.264 2.968 -1.37 1.338
Total Liabilities & Shareholders’ Equity 116.053 186.473 78.258 74.779 239.307
Total Common Shares Outstanding 236.895 235.219 116.231 20.6913 16.6413
Short Term Investments 64.195 80.262 0 51.79
Redeemable Preferred Stock 0 0 0
Total Preferred Shares Outstanding 0
Other Current Assets, Total 1.671 0.957
Long Term Investments 3.865 37.435
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 45.932 54.91 71.556 86.873 103.53
Cash and Short Term Investments 33.089 39.972 56.434 70.524 86.351
Cash & Equivalents 21.669 7.675 18.737 6.329 13.87
Total Receivables, Net 0.662 1.214 1.212 2.81 3.397
Accounts Receivable - Trade, Net 0.662 0.66 0.658 2.256 2.25
Total Inventory 6.683 9.083 8.844 8.284 9.035
Other Current Assets, Total 1.324 1.492 1.74 1.671 1.034
Total Assets 70.727 78.371 96.523 116.053 128.653
Property/Plant/Equipment, Total - Net 14.241 13.703 13.741 14.492 13.944
Intangibles, Net 1.278 1.411 1.506 1.576 1.529
Other Long Term Assets, Total 9.276 8.347 8.762 9.247 7.713
Total Current Liabilities 12.123 10.647 10.877 10.414 9.844
Accounts Payable 4.526 4.281 4.972 3.348 3.637
Accrued Expenses 7.141 5.99 5.449 6.601 5.85
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 0.456 0.376 0.456 0.465 0.357
Total Liabilities 23.474 16.868 16.806 16.408 15.677
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 11.351 6.221 5.929 5.994 5.833
Total Equity 47.253 61.503 79.717 99.645 112.976
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.264 0.24 0.239 0.237 0.237
Additional Paid-In Capital 970.952 966.335 964.162 962.731 960.676
Retained Earnings (Accumulated Deficit) -922.133 -903.815 -883.153 -860.935 -843.045
Other Equity, Total -1.83 -1.257 -1.531 -2.388 -4.892
Total Liabilities & Shareholders’ Equity 70.727 78.371 96.523 116.053 128.653
Total Common Shares Outstanding 264.111 239.97 239.342 236.895 236.783
Total Preferred Shares Outstanding
Short Term Investments 11.42 32.297 37.697 64.195 72.481
Prepaid Expenses 4.174 3.149 3.326 3.584 3.713
Long Term Investments 0 0 0.958 3.865 1.937
Property/Plant/Equipment, Total - Gross 27.172
Accumulated Depreciation, Total -12.68
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -75.561 -62.462 -59.312 -154.201 -61.777
Cash From Operating Activities -58.937 -40.659 -46.675 -73.484 -48.493
Cash From Operating Activities 3.368 2.857 2.898 2.166 2.42
Amortization 7.708 11.254 10.801 10.301 10.868
Deferred Taxes 0.318 0.225 -1.516 -3.224 -3.377
Non-Cash Items 10.185 6.24 11.171 76.825 9.288
Cash Interest Paid 0 0 2.187 1.73
Changes in Working Capital -4.955 1.227 -10.717 -5.351 -5.915
Cash From Investing Activities 47.537 -119.668 -0.003 67.645 -53.481
Capital Expenditures -1.279 -1.368 -0.003 -0.437 -0.77
Cash From Financing Activities -0.332 161.705 53.37 -5.609 26.452
Financing Cash Flow Items -0.35 -1.063 -0.11 -0.499 -2.432
Issuance (Retirement) of Stock, Net 0.018 162.768 50.665 26.315 15.682
Issuance (Retirement) of Debt, Net 0 2.815 -31.425 13.202
Foreign Exchange Effects -0.081 0.376 0.27 0.364 -0.433
Net Change in Cash -11.813 1.754 6.962 -11.084 -75.955
Other Investing Cash Flow Items, Total 48.816 -118.3 0 68.082 -52.711
Cash Taxes Paid -0.165 -0.17
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -22.218 -75.561 -57.671 -38.747 -19.128
Cash From Operating Activities -17.248 -58.937 -44.884 -30.23 -15.943
Cash From Operating Activities 0.813 3.368 2.481 1.72 0.869
Amortization 0.112 7.708 7.601 5.203 2.67
Deferred Taxes 0.091 0.318 0.224 0.169 0.084
Non-Cash Items 1.558 10.185 6.837 3.991 2.303
Changes in Working Capital 2.396 -4.955 -4.356 -2.566 -2.741
Cash From Investing Activities 29.737 47.537 41.21 23.173 23.045
Capital Expenditures -0.064 -1.279 -0.904 -0.443 -0.246
Cash From Financing Activities -0.483 -0.332 -0.332 -0.331 -0.336
Financing Cash Flow Items -0.488 -0.35 -0.35 -0.349 -0.348
Issuance (Retirement) of Stock, Net 0.005 0.018 0.018 0.018 0.012
Foreign Exchange Effects 0.403 -0.081 -0.3 0.239 -0.045
Net Change in Cash 12.409 -11.813 -4.306 -7.149 6.721
Issuance (Retirement) of Debt, Net
Other Investing Cash Flow Items, Total 29.801 48.816 42.114 23.616 23.291
Cash Interest Paid
Cash Taxes Paid -0.19 -0.165 0.079 0.065 -0.029

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Asensus Surgical, Inc. Company profile

Asensus Surgical (ASXC) is a medical device company that engages in digitising the interface between the surgeon and the patient to improve minimally invasive surgery (MIS). 

Founded in 2006, Asensus is headquartered in Durham, North Carolina. It pioneers a new era of performance-guided surgery, using advanced capabilities, like machine vision, augmented intelligence, connectivity and robotics in laparoscopy. 

Asensus has built the foundation of Digital Laparoscopy with the help of its Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to address clinical, cognitive and economic shortcomings in surgery.

The Senhance Surgical System is a multi-port robotic system that provides enhanced control with surgeon eye-tracking camera control & 3D (three dimensional) HD (high definition) vision and enhances precision through tremor filtrations and robotic stabilisation. Additionally, surgeons can have enhanced focus during surgery through Asensus’s optimised ergonomics and the sense of touch (haptics). 

The surgical device that consists of a robotic instrument and a camera for laparoscopic procedures is considered to be the smallest instrument offered in robotics, leading to smaller incisions than traditional robotic surgery. Asensus’ Senhance ultrasonic system is an advanced energy device to deliver controlled energy to ligate and divide tissue.

Asensus Surgical previously developed the SPIDER device and the SurgiBot System. It changed its name from TransEnterix in February 2021. The company went public as TransEnterix in May 2014. It trades on the NYSE American under the ticker ‘ASXC’.

Industry: Medical Equipment, Supplies & Distribution (NEC)

1 Tw Alexander Drive
Suite 160
DURHAM
NORTH CAROLINA 27703
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

ETH/USD

3,166.29 Price
-0.870% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

XRP/USD

0.56 Price
-2.400% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

66,297.70 Price
-0.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

17,222.10 Price
+0.110% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading